On Tuesday, Taysha Gene Therapies Inc (NASDAQ: TSHA) opened higher 1.30% from the last session, before settling in for the closing price of $2.31. Price fluctuations for TSHA have ranged from $1.05 to $3.31 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -63.99% annually for the last half of the decade. Company’s average yearly earnings per share was noted 12.13% at the time writing. With a float of $213.50 million, this company’s outstanding shares have now reached $261.53 million.
In an organization with 73 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 72.63%, operating margin of -1225.78%, and the pretax margin is -1201.08%.
Taysha Gene Therapies Inc (TSHA) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Taysha Gene Therapies Inc is 18.37%, while institutional ownership is 61.43%. The most recent insider transaction that took place on May 30 ’25, was worth 2,062,500. In this transaction 10% Owner of this company bought 750,000 shares at a rate of $2.75, taking the stock ownership to the 2,841,704 shares.
Taysha Gene Therapies Inc (TSHA) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 12.13% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 11.06% during the next five years compared to -63.99% drop over the previous five years of trading.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Trading Performance Indicators
Check out the current performance indicators for Taysha Gene Therapies Inc (TSHA). In the past quarter, the stock posted a quick ratio of 5.35. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 84.76.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.36, a number that is poised to hit -0.08 in the next quarter and is forecasted to reach -0.37 in one year’s time.
Technical Analysis of Taysha Gene Therapies Inc (TSHA)
Let’s dig in a bit further. During the last 5-days, its volume was 2.16 million. That was inferior than the volume of 2.94 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 17.60%.
During the past 100 days, Taysha Gene Therapies Inc’s (TSHA) raw stochastic average was set at 58.90%, which indicates a significant increase from 11.84% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 38.50% in the past 14 days, which was lower than the 106.29% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.42, while its 200-day Moving Average is $1.99. However, in the short run, Taysha Gene Therapies Inc’s stock first resistance to watch stands at $2.45. Second resistance stands at $2.57. The third major resistance level sits at $2.67. If the price goes on to break the first support level at $2.24, it is likely to go to the next support level at $2.14. The third support level lies at $2.02 if the price breaches the second support level.
Taysha Gene Therapies Inc (NASDAQ: TSHA) Key Stats
There are currently 214,662K shares outstanding in the company with a market cap of 611.99 million. Presently, the company’s annual sales total 8,330 K according to its annual income of -89,300 K. Last quarter, the company’s sales amounted to 2,300 K and its income totaled -21,530 K.
